CN105682676B - 利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物 - Google Patents
利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物 Download PDFInfo
- Publication number
- CN105682676B CN105682676B CN201480058075.3A CN201480058075A CN105682676B CN 105682676 B CN105682676 B CN 105682676B CN 201480058075 A CN201480058075 A CN 201480058075A CN 105682676 B CN105682676 B CN 105682676B
- Authority
- CN
- China
- Prior art keywords
- growth factor
- hepatocyte growth
- sequence
- pck
- lateral sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 title claims abstract description 85
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 title claims abstract description 78
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims abstract description 55
- 108010029485 Protein Isoforms Proteins 0.000 title claims abstract description 42
- 102000001708 Protein Isoforms Human genes 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 40
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 40
- 239000002157 polynucleotide Substances 0.000 claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 239000002773 nucleotide Substances 0.000 claims description 52
- 239000013598 vector Substances 0.000 claims description 46
- 125000003729 nucleotide group Chemical group 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 230000002950 deficient Effects 0.000 claims description 13
- 239000013612 plasmid Substances 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 6
- 102000053602 DNA Human genes 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 201000010901 lateral sclerosis Diseases 0.000 abstract description 2
- 208000005264 motor neuron disease Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 89
- 239000003102 growth factor Substances 0.000 description 75
- 210000002569 neuron Anatomy 0.000 description 42
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 230000006907 apoptotic process Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 238000000034 method Methods 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 20
- 230000012010 growth Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 230000010261 cell growth Effects 0.000 description 17
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 241000283690 Bos taurus Species 0.000 description 13
- 230000001605 fetal effect Effects 0.000 description 13
- 210000003494 hepatocyte Anatomy 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 241000701161 unidentified adenovirus Species 0.000 description 11
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 10
- QOSATHPSBFQAML-UHFFFAOYSA-N hydrogen peroxide;hydrate Chemical compound O.OO QOSATHPSBFQAML-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000010899 nucleation Methods 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 102000057308 human HGF Human genes 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000001476 gene delivery Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 241000702421 Dependoparvovirus Species 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000035800 maturation Effects 0.000 description 6
- 230000014511 neuron projection development Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 229960004181 riluzole Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 108010014173 Factor X Proteins 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 101150024147 bax gene Proteins 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 229940012426 factor x Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 230000006909 anti-apoptosis Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 108700041737 bcl-2 Genes Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000000185 intracerebroventricular administration Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GQMMRLBWXCGBEV-YVMONPNESA-N (nz)-n-[(3-nitrophenyl)methylidene]hydroxylamine Chemical compound O\N=C/C1=CC=CC([N+]([O-])=O)=C1 GQMMRLBWXCGBEV-YVMONPNESA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000664887 Homo sapiens Superoxide dismutase [Cu-Zn] Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241001028048 Nicola Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (8)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130126216 | 2013-10-22 | ||
KR10-2013-0126216 | 2013-10-22 | ||
PCT/KR2014/009971 WO2015060650A2 (ko) | 2013-10-22 | 2014-10-22 | 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105682676A CN105682676A (zh) | 2016-06-15 |
CN105682676B true CN105682676B (zh) | 2020-10-23 |
Family
ID=53386224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480058075.3A Active CN105682676B (zh) | 2013-10-22 | 2014-10-22 | 利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10639351B2 (zh) |
EP (1) | EP3061457B1 (zh) |
JP (1) | JP6240337B2 (zh) |
KR (2) | KR101779775B1 (zh) |
CN (1) | CN105682676B (zh) |
AU (1) | AU2014337870B2 (zh) |
BR (1) | BR112016008267A2 (zh) |
CA (1) | CA2926607C (zh) |
ES (1) | ES2773305T3 (zh) |
HK (1) | HK1219873A1 (zh) |
MX (1) | MX2016005006A (zh) |
RU (1) | RU2639582C2 (zh) |
SG (1) | SG11201602452SA (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3046202B1 (fr) * | 2015-12-24 | 2017-12-29 | Snecma | Turboreacteur avec un moyen de reprise de poussee sur le carter inter-compresseurs |
JP7140353B2 (ja) * | 2017-12-29 | 2022-09-22 | ヘリックスミス カンパニー, リミテッド | ハイブリッドhgf遺伝子が導入されたaav(アデノ-関連ウイルス)ベクター |
CA3106085A1 (en) * | 2018-07-17 | 2020-04-23 | Helixmith Co., Ltd. | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs |
CN110577954A (zh) * | 2019-10-12 | 2019-12-17 | 北京万福来生物技术有限责任公司 | 突变的肝细胞生长因子基因及其应用 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0255320A3 (en) | 1986-07-28 | 1989-09-06 | Genzyme Corporation | Production of proteins in myeloma cells |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
NZ232813A (en) | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
CA2022752C (en) | 1989-08-11 | 1998-07-07 | Naomi Kitamura | Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
ATE178354T1 (de) | 1990-07-13 | 1999-04-15 | Snow Brand Milk Products Co Ltd | Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung |
US5661133B1 (en) | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
US7323297B1 (en) | 1992-04-03 | 2008-01-29 | The Regents Of The University Of California | Stabilized polynucleotide complexes and methods |
JP3680114B2 (ja) | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
US5652225A (en) | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
US6143714A (en) | 1994-10-24 | 2000-11-07 | Regeneron Pharmaceuticals, Inc. | Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons |
US20030148968A1 (en) | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
WO2001034208A1 (en) | 1999-11-05 | 2001-05-17 | The Regents Of The University Of California | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
JP3927248B2 (ja) | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Hgf凍結乾燥製剤 |
JP3431633B2 (ja) | 1995-08-29 | 2003-07-28 | アンジェスエムジー株式会社 | Hgf遺伝子からなる医薬 |
US5830879A (en) | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
EP0980428A2 (en) | 1997-05-06 | 2000-02-23 | The Regents Of The University Of California | TECHNIQUES AND COMPOSITIONS FOR TREATING HEART FAILURE AND VENTRICULAR REMODELING BY $i(IN VIVO) DELIVERY OF ANGIOGENIC TRANSGENES |
WO1999036103A1 (en) | 1998-01-16 | 1999-07-22 | Mcgill University | Prevention and treatment of neuropathy by hepatocyte growth factor |
JPH11246433A (ja) | 1998-03-03 | 1999-09-14 | Sumitomo Pharmaceut Co Ltd | 心筋梗塞治療剤 |
JP2002506008A (ja) | 1998-03-09 | 2002-02-26 | セント エリザベス メディカル センター | 血管新生を調整するための組成物及び方法 |
US20040228834A1 (en) | 1998-03-09 | 2004-11-18 | Jeffrey Isner | Compositions and methods for modulating vascularization |
US7276359B1 (en) | 1998-03-13 | 2007-10-02 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
ES2239440T3 (es) | 1998-03-13 | 2005-09-16 | Wyeth | Composicion polinucleotidica, procedimiento para la preparacion y utilizacion de la misma. |
EP1555033A3 (en) | 1998-03-13 | 2005-08-17 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
CA2339378A1 (en) | 1998-08-05 | 2000-02-17 | Sumitomo Pharmaceuticals Co., Ltd. | Preparations containing hepatocyte growth factor for treating ischemic diseases by intramuscular administration |
KR20000046969A (ko) | 1998-12-31 | 2000-07-25 | 이선경 | 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더 |
KR20010108053A (ko) | 1999-10-29 | 2001-12-07 | 무라야마 마사노리 | 당뇨병성 허혈성 질환 유전자 치료 |
EP1889633B1 (en) | 2000-06-27 | 2011-10-26 | AnGes MG, Inc. | Medicinal compositions for angiogenic therapy |
AU8622101A (en) | 2000-09-13 | 2002-03-26 | Chugai Pharmaceutical Co Ltd | Remedies for ischemic diseases |
US20030176347A1 (en) * | 2003-05-14 | 2003-09-18 | Toshikazu Nakamura | Remedies for amyotrophic lateral sclerosis |
JP5442173B2 (ja) * | 2000-09-14 | 2014-03-12 | 敏一 中村 | 筋萎縮性側索硬化症治療剤 |
CN1150035C (zh) | 2000-12-21 | 2004-05-19 | 中国人民解放军军事医学科学院放射医学研究所 | 一种重组质粒及其在疾病防治中的应用 |
EP1361896A2 (en) | 2001-01-23 | 2003-11-19 | Boston Scientific Corporation | Localized myocardial injection method for treating ischemic myocardium |
KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
US20140170116A9 (en) | 2002-08-22 | 2014-06-19 | Marc S. Penn | Method of treating ischemic disorders |
EP1578193A4 (en) | 2002-12-23 | 2011-06-15 | Vical Inc | FREEZING PROCESS FOR NUCLEIC ACID / BLOCK COPOLYMER / CATION SIDE COMPLEXES |
US20050164208A1 (en) | 2004-01-22 | 2005-07-28 | Paul Poulin | Storage of genetic information |
KR100833612B1 (ko) * | 2004-12-29 | 2008-05-30 | 에프씨비파미셀 주식회사 | 간엽 간세포로부터 분화된 신경세포를 유효성분으로함유하는 신경계 질환 치료용 약학 조성물 |
AU2006244639A1 (en) | 2005-03-31 | 2006-11-16 | Mytogen, Inc. | Treatment for heart disease |
US20070212390A1 (en) | 2005-09-22 | 2007-09-13 | Ludwig Institute For Cancer Research | Protease-resistant forms of VEGF-D, method of making and method of use |
CA2628928A1 (en) | 2005-11-10 | 2007-05-24 | Receptor Biologix, Inc. | Hepatocyte growth factor intron fusion proteins |
CN101448939B (zh) | 2006-05-17 | 2011-12-14 | 小山义之 | 用于导入核酸、寡核酸或其衍生物的冷冻干燥体 |
WO2007142651A1 (en) | 2006-06-09 | 2007-12-13 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Methods and compositions for the treatment of neuropathy |
EP2218459B1 (en) | 2007-11-07 | 2012-02-01 | Ono Pharmaceutical Co., Ltd. | Sustained release composition containing sdf-1 |
US20090202606A1 (en) | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
RU2470995C2 (ru) | 2008-04-09 | 2012-12-27 | Вайромед Ко., Лтд. | Лиофилизированные днк-составы для увеличенной экспрессии плазмидной днк |
RU2413524C1 (ru) * | 2009-07-31 | 2011-03-10 | Общество с ограниченной ответственностью "КриоЦентр" | Способ лечения психических и неврологических расстройств |
CN102869776B (zh) | 2009-12-23 | 2017-06-23 | 库尔纳公司 | 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病 |
WO2012025925A1 (en) | 2010-08-24 | 2012-03-01 | Rappaport Family Institute For Research In The Medical Sciences | Methods of improving transplantation using sdf-1alpha |
WO2013037521A1 (en) * | 2011-09-16 | 2013-03-21 | Medical Research Council | Modified hgf-1k1 polypeptide |
WO2013037520A1 (en) * | 2011-09-16 | 2013-03-21 | Glaxo Group Limited | Modified hgf-1k1 polypeptide |
JP2013129661A (ja) * | 2013-02-20 | 2013-07-04 | Toshiichi Nakamura | 筋萎縮性側索硬化症治療剤 |
-
2014
- 2014-10-22 AU AU2014337870A patent/AU2014337870B2/en active Active
- 2014-10-22 RU RU2016119116A patent/RU2639582C2/ru active
- 2014-10-22 CA CA2926607A patent/CA2926607C/en active Active
- 2014-10-22 BR BR112016008267A patent/BR112016008267A2/pt not_active Application Discontinuation
- 2014-10-22 ES ES14856385T patent/ES2773305T3/es active Active
- 2014-10-22 MX MX2016005006A patent/MX2016005006A/es active IP Right Grant
- 2014-10-22 SG SG11201602452SA patent/SG11201602452SA/en unknown
- 2014-10-22 KR KR1020140143377A patent/KR101779775B1/ko active IP Right Grant
- 2014-10-22 JP JP2016546724A patent/JP6240337B2/ja active Active
- 2014-10-22 US US15/030,999 patent/US10639351B2/en active Active
- 2014-10-22 CN CN201480058075.3A patent/CN105682676B/zh active Active
- 2014-10-22 EP EP14856385.1A patent/EP3061457B1/en active Active
-
2016
- 2016-07-06 HK HK16107864.0A patent/HK1219873A1/zh unknown
-
2017
- 2017-08-31 KR KR1020170110892A patent/KR101860452B1/ko active IP Right Grant
Non-Patent Citations (7)
Title |
---|
Disease-dependent reciprocal phosphorylation of serine and tyrosine residues of c-Met/HGF receptor contributes disease retardation of a transgenicmouse model of ALS;Keiichi Kadoyama et al;《Neuroscience Research》;20091231;第65卷;第194-200页 * |
Expression of hepatocyte growth factor and c-Met in the anterior horn cells of the spinal cord in the patients with amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS and familial ALS with superoxide dismutase 1 gene mutation;Shinsuke Kato et al;《Acta Neuropathol》;20031231;第106卷;第112-120页 * |
Hepatocyte growth factor(HGF) atteunates gliosis and motoneurnal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS;KADOYAMA K ET AL;《Neuroscience Research》;20071231;第59卷;第446-456页 * |
Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis:where do we stand?";HENRIQUES A ET AL;《Frontiers in Neuroscience》;20101231;第4卷;第1-14页 * |
Overexpression of HGF Retards Disease Progression and Prolongs Life Span in a Transgenic Mouse Model of ALS;Woong Sun et al;《The Journal of Neuroscience》;20020801;第22卷(第15期);第6537页 * |
肝细胞生长因子与神经***疾病;杨燕等;《国外医学脑血管疾病分册》;20051231;第13卷(第12期);第933-936页 * |
肝细胞生长因子对中枢神经***保护作用的研究进展;杨志华等;《神经损伤与功能重建》;20120131;第7卷(第1期);第59-62页 * |
Also Published As
Publication number | Publication date |
---|---|
ES2773305T3 (es) | 2020-07-10 |
CN105682676A (zh) | 2016-06-15 |
KR20170104129A (ko) | 2017-09-14 |
JP2016534149A (ja) | 2016-11-04 |
EP3061457A2 (en) | 2016-08-31 |
US20160250291A1 (en) | 2016-09-01 |
HK1219873A1 (zh) | 2017-04-21 |
CA2926607A1 (en) | 2015-04-30 |
AU2014337870A1 (en) | 2016-05-05 |
RU2016119116A (ru) | 2017-11-28 |
AU2014337870B2 (en) | 2019-11-28 |
EP3061457B1 (en) | 2020-01-22 |
SG11201602452SA (en) | 2016-05-30 |
CA2926607C (en) | 2018-10-23 |
EP3061457A4 (en) | 2017-06-07 |
KR101779775B1 (ko) | 2017-09-21 |
KR20150047108A (ko) | 2015-05-04 |
JP6240337B2 (ja) | 2017-11-29 |
MX2016005006A (es) | 2016-07-14 |
US10639351B2 (en) | 2020-05-05 |
RU2639582C2 (ru) | 2017-12-21 |
KR101860452B1 (ko) | 2018-05-24 |
BR112016008267A2 (pt) | 2017-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2024020346A (ja) | 筋疾患の治療のための改変aavカプシドポリペプチド | |
JP7263327B2 (ja) | 細胞の遺伝子修飾のための非組込みdnaベクター | |
KR20220107222A (ko) | 마이크로디스트로핀 유전자 치료 작제물 및 이의 용도 | |
TW201920679A (zh) | 眼部疾病之細胞模式及用於眼部疾病的療法 | |
CN105682676B (zh) | 利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物 | |
CN114174520A (zh) | 用于选择性基因调节的组合物和方法 | |
KR20170036085A (ko) | 포유동물 rpe65의 높은 아소머로하이드롤라아제 활성 돌연변이 | |
US20230044444A1 (en) | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery | |
WO2013065913A1 (ko) | Hgf 이형체를 이용한 당뇨병성 신경병증의 유전자 치료 | |
CN116685329A (zh) | 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途 | |
WO2021230385A1 (en) | Method for treating muscular dystrophy by targeting utrophin gene | |
CN114127296A (zh) | Ube3a基因和表达盒及其应用 | |
Takeda et al. | Gene therapy for muscular dystrophies: current status and future prospects | |
JP2023539631A (ja) | Dux4遺伝子を標的とした顔面肩甲上腕型筋ジストロフィーの治療方法 | |
AU2016338565A1 (en) | Nucleic acid molecules containing spacers and methods of use thereof | |
WO2021067611A2 (en) | Compositions and methods for treating alzheimer's disease | |
CN105358690B (zh) | 启动子组合物 | |
WO2015060650A2 (ko) | 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물 | |
WO2024125494A1 (zh) | 一种基因调节的方法及其应用 | |
WO1999036559A1 (en) | Viral vectors expressing self-polymerizing neuronal intermediate filaments and their use | |
TW202229321A (zh) | 核酸構築體、病毒載體及病毒顆粒 | |
KR20240027748A (ko) | Rbm20 돌연변이의 게놈 편집 | |
KR20200056428A (ko) | 변이체 RNAi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1219873 Country of ref document: HK |
|
CB02 | Change of applicant information |
Address after: Seoul, South Kerean Applicant after: Hellis Messi Co., Ltd. Address before: Seoul, South Kerean Applicant before: Viromed Co., Ltd. |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Han Guo Shouer Applicant after: Helismith Corporation Address before: Han Guo Shouer Applicant before: Hellis Messi Co., Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |